Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Market: Pharmaceuticals and Healthcare

Global, 39 pages report, published by Global Markets Direct

Keywords : Current R&D Portfolio of Cubist Pharmaceuticals, Inc.; Cubist Pharmaceuticals, Inc. - Key Therapeutics; Cubist Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Cubist Pharmaceuticals, Inc. - News; Cubist Pharmaceuticals, Inc. - Latest Updates; Cubist Pharmaceuticals, Inc. - Pipeline; Cubist Pharmaceuticals, Inc. - Discontinued/Dormant Projects

Report ThumbnailAugust-2013
Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Cubist Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cubist Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cubist Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cubist Pharmaceuticals, Inc. - Brief Cubist Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cubist Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cubist Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cubist Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Cubist Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cubist Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cubist Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cubist Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cubist Pharmaceuticals, Inc. and identify potential opportunities in those areas.
  • List of Figures
  • Cubist Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
  • Cubist Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 9
  • Cubist Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 10
  • Cubist Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2013 11
  • Cubist Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 20
  • Cubist Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 23
  • Cubist Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 24
  • List of Tables
  • Cubist Pharmaceuticals, Inc., Key Information 5
  • Cubist Pharmaceuticals, Inc., Key Facts 5
  • Cubist Pharmaceuticals, Inc. - Pipeline by Indication, 2013 8
  • Cubist Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 9
  • Cubist Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 10
  • Cubist Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2013 11
  • Cubist Pharmaceuticals, Inc. - Phase III, 2013 12
  • Cubist Pharmaceuticals, Inc. - Phase II, 2013 13
  • Cubist Pharmaceuticals, Inc. - Preclinical, 2013 14
  • Cubist Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 21
  • Cubist Pharmaceuticals, Inc. - Pipeline By Target, 2013 22
  • Cubist Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 23
  • Cubist Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 24
  • Cubist Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 25
  • Cubist Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 32
  • Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2013 33
  • Cubist Pharmaceuticals, Inc., Subsidiaries 37
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Cubist Pharmaceuticals, Inc. Snapshot 5
  • Cubist Pharmaceuticals, Inc. Overview 5
  • Key Information 5
  • Key Facts 5
  • Cubist Pharmaceuticals, Inc. - Research and Development Overview 6
  • Key Therapeutic Areas 6
  • Cubist Pharmaceuticals, Inc. - Pipeline Review 9
  • Pipeline Products by Stage of Development 9
  • Pipeline Products - Monotherapy 10
  • Pipeline Products - Combination Treatment Modalities 11
  • Cubist Pharmaceuticals, Inc. - Pipeline Products Glance 12
  • Cubist Pharmaceuticals, Inc. - Late Stage Pipeline 12
  • Phase III Products/Combination Treatment Modalities 12
  • Cubist Pharmaceuticals, Inc. Clinical Stage Pipeline Products 13
  • Phase II Products/Combination Treatment Modalities 13
  • Cubist Pharmaceuticals, Inc. - Early Stage Pipeline Products 14
  • Preclinical Products/Combination Treatment Modalities 14
  • Cubist Pharmaceuticals, Inc. - Drug Profiles 15
  • Anti-Bacterial Compounds Program 15
  • Product Description 15
  • Mechanism of Action 15
  • R&D Progress 15
  • bevenopran 16
  • Product Description 16
  • Mechanism of Action 16
  • R&D Progress 16
  • CAMORs 17
  • Product Description 17
  • Mechanism of Action 17
  • R&D Progress 17
  • CB-027 18
  • Product Description 18
  • Mechanism of Action 18
  • R&D Progress 18
  • surotomycin 19
  • Product Description 19
  • Mechanism of Action 19
  • R&D Progress 19
  • Cubist Pharmaceuticals, Inc. - Pipeline Analysis 20
  • Cubist Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 20
  • Cubist Pharmaceuticals, Inc. - Pipeline Products By Target 22
  • Cubist Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 23
  • Cubist Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 24
  • Cubist Pharmaceuticals, Inc. - Recent Pipeline Updates 25
  • Cubist Pharmaceuticals, Inc. - Dormant Projects 32
  • Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products 33
  • Discontinued Pipeline Product Profiles 33
  • (libivirumab + exbivirumab) 33
  • ADL-5747 33
  • ADL-5859 33
  • CB-182,804 34
  • CB-183872 34
  • CB-625 34
  • ecallantide 34
  • Cubist Pharmaceuticals, Inc. - Company Statement 35
  • Cubist Pharmaceuticals, Inc. - Locations And Subsidiaries 37
  • Head Office 37
  • Other Locations & Subsidiaries 37
  • Appendix 38
  • Methodology 38
  • Coverage 38
  • Secondary Research 38
  • Primary Research 38
  • Expert Panel Validation 38
  • Contact Us 39
  • Disclaimer 39

Please select a license type

Share

Related Products

Global Markets DirectCubist Pharmaceuticals, Inc. - Product Pipeline Review - 2013Product ThumbnailCubist Pharmaceuticals, Inc. - Product Pipeline Review - 2013, Industry ReportProduct #: 113361
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved